miR-21、miR-155在胰腺癌患者血浆中的表达及临床意义  

Expression of miR-21 and miR-155 in plasma of patients with pancreatic cancer and its clinical significance

作　　者：阿孜古力.阿不来提 彭媛媛[1] 努尔麦麦提.叶尔逊 丁永年[1] ARZUGUL Ablet;PENG Yuan-yuan;NUERMAIMAITI Yerson(Department of Gastroenterology,The Second Affiliated Hospital of Xinjiang Medical University,Urumqi Xinjiang 830000,China)

机构地区：[1]新疆维吾尔自治区新疆医科大学第二附属医院消化内科,新疆乌鲁木齐830000

出　　处：《临床和实验医学杂志》2018年第13期1375-1378,共4页Journal of Clinical and Experimental Medicine

基　　金：新疆维吾尔自治区自然科学基金(编号:XYDCX201639)

摘　　要：目的研究微小RNA-21(miR-21)、微小RNA-155(miR-155)在胰腺癌早期患者血清中的表达水平,探讨其与胰腺癌发病之间的相互关系。方法回顾性采集42例胰腺癌患者、42例慢性胰腺炎患者、42例健康对照组患者血液。利用荧光定量PCR仪对血液中miR-21、miR-155的表达水平进行检测,比较miR-21、miR-155与胰腺疾病临床特征之间的关系,绘制出ROC曲线,判定miR-21与miR-155表达水平与胰腺癌之间存在的联系。结果 miR-21、miR-155在胰腺癌患者血清中表达水平(3.88±3.12,5.29±4.37)高于慢性胰腺炎患者、健康对照组的表达水平(1.09±2.74、0.14±2.59,0.31±3.73、-1.31±3.47),差异有统计学意义(P<0.05);慢性胰腺炎患者血浆中miR-21、miR-155表达水平(1.09±2.74,0.31±3.73)稍高于健康对照组(0.14±2.59,-1.31±3.47),但差异无统计学意义(P>0.05);miR-21、miR-155在胰腺癌与健康对照组、胰腺癌与慢性胰腺炎组、胰腺癌与慢性胰腺癌+健康对照组3组人群中对胰腺癌的诊断效能的曲线下面积(AUC)分别为0.863(95%CI:0.779,0.938)、0.747(95%CI:0.648,0.833)和0.793(95%CI:0.714,0.873);在鉴别胰腺癌与健康对照组准确性为73.12%、胰腺癌与慢性胰腺炎中为67.81%;在胰腺癌+慢性胰腺炎+健康对照组中诊断胰腺癌的敏感度和特异度分别为70.31%与68.92%,准确性为69.61%。结论胰腺癌患者血浆miR-21与miR-155的表达水平明显异常,可作为胰腺癌早期诊断的依据。Objective To study the expression of miR-21 and miR-155 in the serum of patients with early pancreatic cancer and to explore the relationship between them and the pathogenesis of pancreatic cancer. Methods Blood samples were collected from 42 patients with pancreatic cancer,42 patients with chronic pancreatitis and 42 healthy controls. The expression level of miR-21 and miR-155 in blood was detected by fluorescence quantitative PCR. The expression level of miR-21 and miR-155 was measured. To analyze the relationship between miR-21 and miR-155 and pancreatic disease,the ROC curve was drawn to determine the relationship between the expression level of miR-21 and miR-155 and pancreatic cancer. Results The expression levels of miR-21 and miR-155 in serum of patients with pancreatic cancer were（ 3. 88± 3. 12,5. 29 ± 4. 37）,higher than that of chronic pancreatitis and healthy control group（ 1. 09 ± 2. 74 and 0. 14 ± 2. 59,0. 31 ± 3. 73,-1. 31± 3. 47）,and the difference was statistically significant（ P〈0. 05）. The expression levels of miR-21 and miR-155 in plasma of patients with chronic pancreatitis were higher than those in healthy controls（ 0. 14 ± 2. 59,-1. 31 ± 3. 47）,but the difference was not statistically significant;the AUC scores of the diagnostic efficacy of pancreatic cancer in the healthy control group were 0. 863（ 95% CI： 0. 779,0. 938）,0. 747（ 95%CI： 0. 648,0. 833） and 0. 793（ 95% CI： 0. 714,0. 873） of pancreatic cancer and healthy control group,pancreatic cancer and chronic pancreatitis group,pancreatic cancer and chronic pancreatic cancer; The accuracy in cancer and healthy control group was 73. 12%,while in the pancreatic cancer and chronic pancreatitis group was 67. 81%; The diagnosis of pancreatic cancer sensitivity and specificity in pancreatic cancer ＋ chronic pancreatitis ＋ healthy control group were 70. 31% with 68. 92%,the accuracy was 69. 61%. Conclusion The expression levels of miR-21 and miR-155 in pancreatic cancer patients are significantly ab

关 键 词：胰腺癌 MIR-21 MIR-155 ROC曲线 

分 类 号：R735.9[医药卫生—肿瘤]